Welcome to our dedicated page for Selecta Biosciences news (Ticker: SELB), a resource for investors and traders seeking the latest updates and insights on Selecta Biosciences stock.
Selecta Biosciences, Inc. (symbol: SELB) is a clinical-stage biopharmaceutical company dedicated to enhancing the efficacy of biologic therapies by reducing unwanted immune responses. The company's innovative approach leverages its proprietary tolerogenic Synthetic Vaccine Particles (SVP™) technology, which is designed to enable a wide range of biologics, particularly for rare and serious diseases that lack effective treatment options.
Selecta's current pipeline features SVP-enabled enzyme, oncology, and gene therapies. Leading the pipeline is SEL-212, a promising candidate in Phase 2 trials targeting severe gout. SEL-212 aims to alleviate debilitating symptoms such as flares and gouty arthritis, offering much-needed relief to patients. Another noteworthy candidate is SEL-403, a combination therapy comprising SVP-Rapamycin and LMB-100, which entered Phase 1 trials in 2018 for treating malignant pleural or peritoneal mesothelioma.
In addition to enzyme and oncology therapies, Selecta is developing gene therapy product candidates designed for rare metabolic disorders. These candidates hold the potential to enable repeat dosing and long-term efficacy. The company’s research endeavors are backed by a series of collaborations and partnerships that bolster its scientific and commercial capabilities.
The company's latest news highlights significant progress in its clinical trials and partnerships. Notable developments include updates on the potential of its Descartes-08 and Descartes-15 therapies to treat myasthenia gravis and other autoimmune diseases, as well as advancements in RNA Armory® technology.
Selecta continues to focus on mitigating risks inherent in clinical trials, regulatory processes, and funding requirements. The company's strategic initiatives and forward-looking statements are guided by its commitment to addressing unmet medical needs and bringing innovative therapies to market.
Selecta Biosciences, Inc. (NASDAQ: SELB) announced a conference call scheduled for May 13, 2021, at 8:30 a.m. ET to discuss its financial results for Q1 2021 and provide a business update. The company is focused on leveraging its ImmTOR™ platform to develop therapies targeting unwanted immune responses. Selecta's pipeline includes enzyme therapies, gene therapies, and treatments for autoimmune diseases, showcasing its potential to enhance biologic therapies and restore self-tolerance. Investors can access the call via phone or through the company's website.
Selecta Biosciences (NASDAQ: SELB) announced three key presentations at the upcoming 24th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) from May 11-14, 2021. These presentations will focus on the ImmTOR platform's capabilities to reduce AAV immunogenicity and enable redosing of gene therapies for genetic disorders. Dr. Takashi Kei Kishimoto emphasized the importance of maintaining therapeutic activity, especially for pediatric patients. The results aim to validate ImmTOR's efficacy, with presentations scheduled for May 11, 2021, showcasing advancements in gene therapy.
Selecta Biosciences has gained full ownership of the Methylmalonic Acidemia (MMA) program from Asklepios BioPharmaceutical due to AskBio's internal portfolio prioritization. Selecta aims to advance the MMA-101 and ImmTOR combination through clinical development independently. However, their IND submission is now delayed until at least Q4 2021 due to manufacturing issues. Meanwhile, the SEL-399 trial is on track to provide topline data in Q4 2021, evaluating the safety and efficacy of ImmTOR in gene therapy.
Selecta Biosciences, Inc. (NASDAQ: SELB) announced that CEO Carsten Brunn, Ph.D., will participate in the virtual 20th Annual Needham Healthcare Conference from April 12-15, 2021. The fireside chat is scheduled for April 13 at 3:00 p.m. ET, with a webcast available for viewing.
Additionally, Selecta is enhancing its ImmTOR™ platform to develop therapies that reduce unwanted immune responses and is entering clinical trials for gene therapies. Recent licensing of SEL-212 for chronic refractory gout underscores its innovative approach.
Selecta Biosciences, Inc. (NASDAQ: SELB) reported its fourth quarter and annual results, highlighting a revenue increase to $12.0 million in Q4 2020 from $6.7 million in Q4 2019, driven primarily by a partnership with Sobi for the SEL-212 program. The company also detailed significant advancements in its pipelines, including the initiation of the first-in-human study for ImmTOR in 2021 and expectations for the MMA-101 gene therapy to enter clinics in Q2 2021. Despite a net loss of $15.4 million in Q4, Selecta maintains sufficient cash reserves to support operations into Q2 2023.
Selecta Biosciences (NASDAQ: SELB) will host a conference call on March 11, 2020, at 8:30 a.m. ET to discuss its financial results for Q4 and full-year 2020 along with operational highlights. The company leverages its ImmTOR™ platform to develop therapies aimed at mitigating unwanted immune responses. Notably, it plans to enter clinical trials for its AAV gene therapies aimed at treating methylmalonic acidemia in early 2021. The licensing of its SEL-212 product candidate for chronic refractory gout to Sobi further highlights Selecta's strategic advancements.
On March 1, 2021, Selecta Biosciences (NASDAQ: SELB) announced that CEO Carsten Brunn, Ph.D., and CFO Brad Dahms will participate in the virtual H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will be available on-demand starting at 7 a.m. EST on March 9. Selecta is known for its ImmTOR™ platform, which aims to develop therapies that address unwanted immune responses. Their upcoming clinical trial focuses on treatments for methylmalonic acidemia in collaboration with AskBio.
Selecta Biosciences, Inc. (NASDAQ: SELB) announced a pivotal study published in Science Advances, demonstrating that its ImmTOR platform significantly enhances gene therapy efficacy. The study shows that co-administering ImmTOR nanoparticles with AAV vectors increases hepatic vector copy numbers and transgene expression. This breakthrough suggests ImmTOR may enable lower doses of AAV, improve safety, and address immunogenicity. The findings validate the role of ImmTOR in Selecta's gene therapy pipeline, particularly for treatments like methylmalonic acidemia and OTC deficiency.
Selecta Biosciences (NASDAQ: SELB) and Asklepios BioPharmaceutical have initiated a Phase 1 dose-escalation trial of SEL-399 to assess ImmTOR's impact on antibody responses to AAV8 capsids in healthy volunteers. Conducted in Belgium, the trial seeks to enroll up to 45 subjects to determine the optimal ImmTOR dosage for reducing antibody formation. This study is significant, being the first human trial combining ImmTOR with AAV capsid technology. Initial results are expected in Q4 2021 and may inform future clinical studies for more effective gene therapy applications.
Selecta Biosciences, Inc. (NASDAQ: SELB) announced that CEO Carsten Brunn, Ph.D., will deliver a corporate update and participate in investor meetings at the SVB Leerink 10th Annual Global Healthcare Conference, scheduled for February 24-26, 2021. Brunn's presentation will take place on February 26 at 10 a.m. ET and will be accessible via the conference portal. Selecta is focused on developing tolerogenic therapies through its ImmTOR™ platform, with clinical trials for its AAV gene therapy anticipated to start early in 2021.
FAQ
What is the market cap of Selecta Biosciences (SELB)?
What does Selecta Biosciences, Inc. specialize in?
What is SEL-212?
What is the significance of SVP™ technology?
What are the current projects in Selecta's pipeline?
What recent achievements has Selecta Biosciences made?
What partnerships does Selecta Biosciences have?
What is SEL-403?
How does Selecta Biosciences address risks in clinical trials?
What are the potential applications of Selecta's gene therapy candidates?
What are the key developments in Selecta's latest news?
